XML 77 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue (Tables)
 12 Months Ended
Apr. 24, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The table below illustrates net sales by segment and division for fiscal years 2020, 2019, and 2018:
 
 Net Sales by Fiscal Year(1)
(in millions)202020192018
Cardiac Rhythm & Heart Failure$5,141  $5,849  $5,947  
Coronary & Structural Heart3,541  3,730  3,562  
Aortic, Peripheral & Venous1,786  1,926  1,845  
Cardiac and Vascular Group10,468  11,505  11,354  
Surgical Innovations5,513  5,753  5,537  
Respiratory, Gastrointestinal, & Renal2,839  2,725  3,179  
Minimally Invasive Therapies Group8,352  8,478  8,716  
Brain Therapies2,922  2,938  2,354  
Spine2,503  2,654  2,668  
Specialty Therapies1,193  1,307  1,556  
Pain Therapies1,107  1,284  1,165  
Restorative Therapies Group7,725  8,183  7,743  
Diabetes Group2,368  2,391  2,140  
Total$28,913  $30,557  $29,953  
(1)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
The table below includes net sales by market geography and segment for fiscal years 2020, 2019, and 2018:
 Net Sales by Fiscal Year(4)
(in millions)202020192018
U.S.(1)
$5,062  $5,750  $5,681  
Non-U.S. Developed Markets(2)
3,5193,7673,790
Emerging Markets(3)
1,8871,9881,883
Cardiac and Vascular Group10,46811,50511,354
U.S.(1)
3,5323,6303,804
Non-U.S. Developed Markets(2)
3,1693,2503,378
Emerging Markets(3)
1,6511,5981,534
Minimally Invasive Therapies Group8,3528,4788,716
U.S.(1)
5,1225,4785,164
Non-U.S. Developed Markets(2)
1,6591,7591,720
Emerging Markets(3)
945946859
Restorative Therapies Group7,7258,1837,743
U.S.(1)
1,2041,3361,226
Non-U.S. Developed Markets(2)
940855739
Emerging Markets(3)
224200175
Diabetes Group2,3682,3912,140
U.S.(1)
14,91916,19415,875
Non-U.S. Developed Markets(2)
9,2879,6319,627
Emerging Markets(3)
4,7074,7324,451
Total $28,913  $30,557  $29,953  
(1)U.S. includes the United States and U.S. territories.
(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.
(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.
(4)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.